{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T14:14:50Z","timestamp":1769264090828,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Hospitals Authority Clinical medicine Development of special funding support","award":["XMLX 202127"],"award-info":[{"award-number":["XMLX 202127"]}]},{"DOI":"10.13039\/501100015850","name":"The Digestive Medical Coordinated Development Center of Beijing Hospitals Authority","doi-asserted-by":"crossref","award":["No. XXZ0302"],"award-info":[{"award-number":["No. XXZ0302"]}],"id":[{"id":"10.13039\/501100015850","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015850","name":"The Digestive Medical Coordinated Development Center of Beijing Hospitals Authority","doi-asserted-by":"crossref","award":["XXT28"],"award-info":[{"award-number":["XXT28"]}],"id":[{"id":"10.13039\/501100015850","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Science and Technology Major Project of China","award":["No. 2017ZX10201201-001-006"],"award-info":[{"award-number":["No. 2017ZX10201201-001-006"]}]},{"name":"National Science and Technology Major Project of China","award":["2017ZX10201201-002-006"],"award-info":[{"award-number":["2017ZX10201201-002-006"]}]},{"name":"National Science and Technology Major Project of China","award":["2018ZX10715-005-003-005"],"award-info":[{"award-number":["2018ZX10715-005-003-005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Agents Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cefminox sodium is an antimicrobial agent with broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria. Cefminox sodium has high security in clinical practice for its few adverse effects such as coagulation dysfunction, which is rare in clinical treatment. Even in patients suffering from chronic liver disease with coagulation dysfunction, it rarely leads to further deterioration of coagulation function. Therefore, patients with chronic liver disease develop severe coagulation dysfunction during the application of cefminox sodium, which is often mistaken for worsening of liver disease other than considered to be the side effect of the drug. Therefore, we report a 55-year-old female patient with liver cirrhosis and hepatocellular carcinoma treated with cefminox sodium intravenously twice for peritonitis. During the treatments, severe coagulopathy occurred, and the coagulation function quickly recovered after drug withdrawal. The diagnosis and treatment of this patient provides us with ideas for dealing with similar problems in clinical practice in the future.<\/jats:p>","DOI":"10.1186\/s13027-022-00446-y","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T13:05:52Z","timestamp":1655384752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Severe coagulopathy caused by cefminox sodium in a liver cirrhosis patient: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Shuling","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyue","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3233-5473","authenticated-orcid":false,"given":"Minghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4108-7037","authenticated-orcid":false,"given":"Yao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"issue":"5","key":"446_CR1","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.11553\/antibiotics1968b.38.1178","volume":"38","author":"H Nishidai","year":"1985","unstructured":"Nishidai H, Hashimoto I, Mikami J, et al. Cefminox concentration in tissues and clinical efficacy of cefminox in acute peritonitis. Jpn J Antibiot. 1985;38(5):1178\u201394. https:\/\/doi.org\/10.11553\/antibiotics1968b.38.1178.","journal-title":"Jpn J Antibiot"},{"issue":"6","key":"446_CR2","first-page":"361","volume":"10","author":"S Omoto","year":"1990","unstructured":"Omoto S, Watanabe S. Efficacy of cefminox in the treatment of bacterial infections. Int J Clin Pharmacol Res. 1990;10(6):361\u20138.","journal-title":"Int J Clin Pharmacol Res"},{"issue":"5","key":"446_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s150100070027","volume":"28","author":"AJ Torres","year":"2000","unstructured":"Torres AJ, Valladares LD, Jover JM, et al. Cefminox versus metronidazole plus gentamicin intra-abdominal infections: a prospective randomized controlled clinical trial. Infection. 2000;28(5):318\u201322. https:\/\/doi.org\/10.1007\/s150100070027.","journal-title":"Infection"},{"issue":"3","key":"446_CR4","first-page":"149","volume":"33","author":"T Mayama","year":"1995","unstructured":"Mayama T, Koyama Y, Sebata K, et al. Postmarketing surveillance on side-effects of cefminox sodium (Meicelin). Int J Clin Pharmacol Ther. 1995;33(3):149\u201355.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"9","key":"446_CR5","first-page":"1588","volume":"43","author":"K Yasunaga","year":"1990","unstructured":"Yasunaga K, Nakagawa M, Kakishita E. Study on effects of cefminox sodium on blood coagulation system. Jpn J Antibiot. 1990;43(9):1588\u2013602.","journal-title":"Jpn J Antibiot"},{"issue":"12","key":"446_CR6","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1016\/j.clinthera.2021.10.005","volume":"43","author":"S Wu","year":"2021","unstructured":"Wu S, Wu G, Wu H. A comparison of coagulation function in patients receiving aspirin and cefoperazone-sulbactam with and without vitamin K1: a retrospective, observational study. Clin Ther. 2021;43(12):e335\u201345. https:\/\/doi.org\/10.1016\/j.clinthera.2021.10.005.","journal-title":"Clin Ther"},{"issue":"2","key":"446_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3143\/geriatrics.56.204","volume":"56","author":"Y Furumi","year":"2019","unstructured":"Furumi Y, Shimizu S, Ogawa Y, et al. A suspicious case of coagulation disorder caused by vitamin K deficiency associated with fasting and antibiotic. Nihon Ronen Igakkai Zasshi. 2019;56(2):204\u20138. https:\/\/doi.org\/10.3143\/geriatrics.56.204.","journal-title":"Nihon Ronen Igakkai Zasshi"},{"issue":"3","key":"446_CR8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/1120009X.2020.1730087","volume":"32","author":"E Guclu","year":"2020","unstructured":"Guclu E, Kaya G, Ogutlu A, et al. The effect of cefoperazone sulbactam and piperacillin tazobactam on mortality in Gram-negative nosocomial infections. J Chemother. 2020;32(3):118\u201323. https:\/\/doi.org\/10.1080\/1120009X.2020.1730087.","journal-title":"J Chemother"},{"issue":"1","key":"446_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s40800-019-0100-0","volume":"6","author":"HR Hu","year":"2019","unstructured":"Hu HR. Fatal vitamin K-dependent coagulopathy associated with cefoperazone\/sulbactam: a case report. Drug Saf Case Rep. 2019;6(1):6. https:\/\/doi.org\/10.1007\/s40800-019-0100-0.","journal-title":"Drug Saf Case Rep"},{"issue":"3","key":"446_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/14740338.2020.1713090","volume":"19","author":"W Wang","year":"2020","unstructured":"Wang W, Liu Y, Yu C, et al. Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study. Expert Opin Drug Saf. 2020;19(3):339\u201347. https:\/\/doi.org\/10.1080\/14740338.2020.1713090.","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"446_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7860\/JCDR\/2016\/19694.8316","volume":"10","author":"GR Katukuri","year":"2016","unstructured":"Katukuri GR, Maddala RN, Ramamoorthi K, et al. Cefoperazone induced gastrointestinal bleeding. J Clin Diagn Res. 2016;10(8):10\u20131. https:\/\/doi.org\/10.7860\/JCDR\/2016\/19694.8316.","journal-title":"J Clin Diagn Res"},{"issue":"20","key":"446_CR12","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.3390\/ijerph16203937","volume":"16","author":"GH Park","year":"2019","unstructured":"Park GH, Kim S, Kim MS, et al. The association between cephalosporin and hypoprothrombinemia: a systematic review and meta-analysis. Int J Environ Res Public Health. 2019;16(20):3937. https:\/\/doi.org\/10.3390\/ijerph16203937.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"446_CR13","doi-asserted-by":"publisher","first-page":"G171","DOI":"10.1152\/ajpgi.00402.2017","volume":"315","author":"A Pant","year":"2018","unstructured":"Pant A, Kopec AK, Luyendyk JP. Role of the blood coagulation cascade in hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol. 2018;315(2):G171\u20136. https:\/\/doi.org\/10.1152\/ajpgi.00402.2017.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"446_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"issue":"8449","key":"446_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/s0140-6736(85)90291-0","volume":"2","author":"K Motohara","year":"1985","unstructured":"Motohara K, Endo F, Matsuda I. Effect of vitamin K administration on acarboxy prothrombin (PIVKA-II) levels in newborns. Lancet. 1985;2(8449):242\u20134. https:\/\/doi.org\/10.1016\/s0140-6736(85)90291-0.","journal-title":"Lancet"},{"issue":"6","key":"446_CR16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/archpedi.1989.02150180064022","volume":"143","author":"T Shinzawa","year":"1989","unstructured":"Shinzawa T, Mura T, Tsunei M, et al. Vitamin K absorption capacity and its association with vitamin K deficiency. Am J Dis Child. 1989;143(6):686\u20139. https:\/\/doi.org\/10.1001\/archpedi.1989.02150180064022.","journal-title":"Am J Dis Child"},{"issue":"8","key":"446_CR17","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.3390\/nu13082580","volume":"13","author":"S Dahlberg","year":"2021","unstructured":"Dahlberg S, Sch\u00f6tt U, Eriksson E\u00c4, et al. Intravenous vitamin K1 for the correction of prolonged prothrombin times in non-bleeding critically ill patients: a prospective observational study. Nutrients. 2021;13(8):2580. https:\/\/doi.org\/10.3390\/nu13082580.","journal-title":"Nutrients"}],"container-title":["Infectious Agents and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-022-00446-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13027-022-00446-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-022-00446-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T13:13:17Z","timestamp":1655385197000},"score":1,"resource":{"primary":{"URL":"https:\/\/infectagentscancer.biomedcentral.com\/articles\/10.1186\/s13027-022-00446-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1186\/s13027-022-00446-y","relation":{},"ISSN":["1750-9378"],"issn-type":[{"value":"1750-9378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Beijing Ditan Hospital, and was performed in accordance with the 1975 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interests that are directly or indirectly related to the work submitted for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}